Drug Trial Radar · NCT02080364
Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: May 7, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
880
Actual
Start
Apr 2015
Primary completion
Jun 1, 2018
Study completion Jun 1, 2018
Sponsor
- Lead sponsor
- vTv TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 6, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 18 months.
Conditions
- Alzheimer's Disease
Interventions
AzeliragonDrug
Azeliragon 5mg administered orally, once daily for 18 months
PlaceboDrug
Placebo administered orally, once daily for 18 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) Total ScoreTime frame: Baseline and 18 months (A-Study); baseline and 12 months (B-Study)
- Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-sb)Time frame: Baseline and 18 months (A-Study); baseline and 12 months (B-Study)
Locations
115 sites in 7 countries. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Phoenix, Arizona
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
Tucson, Arizona
Site not named
Bellflower, California
Site not named
Costa Mesa, California
Site not named
Fullerton, California
Site not named
Glendale, California
Site not named
Imperial, California
Site not named
Irvine, California
Site not named
Laguna Hills, California
Site not named
Long Beach, California
Site not named
Long Beach, California
Site not named
Orange, California
Site not named
Riverside, California
Site not named
San Bernardino, California
Site not named
San Francisco, California
Site not named
Santa Ana, California
Site not named
Atlantis, Florida
Site not named
Brooksville, Florida
Site not named
Delray Beach, Florida
Site not named
Hallandale, Florida
Site not named
Hialeah, Florida
Site not named
Jacksonville, Florida
Site not named
Lake Worth, Florida
Site not named
Leesburg, Florida
Site not named
Miami, Florida
Site not named
Miami, Florida
Site not named
Miami Beach, Florida
Site not named
Miami Lakes, Florida
Site not named
Miami Lakes, Florida
Site not named
Orlando, Florida
Site not named
Pensacola, Florida
Site not named
Sarasota, Florida
Site not named
Sunrise, Florida
Site not named
Atlanta, Georgia
Site not named
Columbus, Georgia
Site not named
Chicago, Illinois
Site not named
Fairway, Kansas
Showing 40 of 115 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.